EA200300640A1 - Фармацевтические композиции, усиливающие иммуногенность антигенов со слабой иммуногенностью - Google Patents

Фармацевтические композиции, усиливающие иммуногенность антигенов со слабой иммуногенностью

Info

Publication number
EA200300640A1
EA200300640A1 EA200300640A EA200300640A EA200300640A1 EA 200300640 A1 EA200300640 A1 EA 200300640A1 EA 200300640 A EA200300640 A EA 200300640A EA 200300640 A EA200300640 A EA 200300640A EA 200300640 A1 EA200300640 A1 EA 200300640A1
Authority
EA
Eurasian Patent Office
Prior art keywords
immunogeness
immunogenicity
antigens
strengthening
weak
Prior art date
Application number
EA200300640A
Other languages
English (en)
Other versions
EA005138B1 (ru
Inventor
Луис Энрике Фернандес Молина
Белинда Санчес Рамирес
Эдуардо Рауль Суарес Пестана
Анабель Де Ла Баррера Айра
Сирсе Меса Пардильо
Хоэль Де Леон Дельгадо
Йильдиан Диас Родригес
Роландо Перес Родригес
Original Assignee
Сентро Де Инмунология Молекулар
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CU20000285A external-priority patent/CU23000A1/es
Priority claimed from CU20010167A external-priority patent/CU23009A1/es
Application filed by Сентро Де Инмунология Молекулар filed Critical Сентро Де Инмунология Молекулар
Publication of EA200300640A1 publication Critical patent/EA200300640A1/ru
Publication of EA005138B1 publication Critical patent/EA005138B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Изобретение относится к иммунологии, точнее к иммуногенным композициям, содержащим пептиды, полипептиды, белки и последовательности соответствующих им ДНК, клетки или их лизаты и протеолипосомы очень малого размера (VSSP), последние образуются путем связывания белкового комплекса наружной мембраны (CPME) Neisseria meningitidis с ганглиозидами посредством гидрофобных связей. В частности, в изобретении демонстрируют, как получать указанные иммуностимулирующие композиции, которые способны генерировать антиген-специфические иммунные ответы даже у иммунологически скомпрометированных хозяев, таких как пациенты, страдающие раком или хроническими вирусными или бактериальными инфекциями. Введением разработанных в изобретении вакцинных композиций пациентам можно восстанавливать участки их иммунной системы. Разработанные в изобретении вакцинные композиции можно применять для предупреждения или лечения инфекционных, злокачественных или аутоиммунных заболеваний.Отчет о международном поиске был опубликован 2002.12.27.
EA200300640A 2000-12-06 2001-12-06 Фармацевтические композиции, усиливающие иммуногенность антигенов со слабой иммуногенностью EA005138B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CU20000285A CU23000A1 (es) 2000-12-06 2000-12-06 Composiciones vacunales para la inmunoterapia activa específica del cáncer
CU20010167A CU23009A1 (es) 2001-07-12 2001-07-12 Preparaciones para potenciar la inmunogenicidad depreparaciones para potenciar la inmunogenicidad de antígenos poco inmunogénicos antígenos poco inmunogénicos
PCT/CU2001/000010 WO2002045746A2 (es) 2000-12-06 2001-12-06 Composiciones farmaceuticas para potenciar la inmunogenicidad de antigenos poco inmunogenicos

Publications (2)

Publication Number Publication Date
EA200300640A1 true EA200300640A1 (ru) 2003-12-25
EA005138B1 EA005138B1 (ru) 2004-12-30

Family

ID=38812545

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200300640A EA005138B1 (ru) 2000-12-06 2001-12-06 Фармацевтические композиции, усиливающие иммуногенность антигенов со слабой иммуногенностью

Country Status (20)

Country Link
US (1) US7776342B2 (ru)
EP (1) EP1356822B1 (ru)
JP (1) JP4210519B2 (ru)
KR (1) KR100850473B1 (ru)
CN (1) CN1291755C (ru)
AR (1) AR031638A1 (ru)
AT (1) ATE485833T1 (ru)
AU (2) AU2002221519B2 (ru)
BR (1) BRPI0116013B8 (ru)
CA (1) CA2431188C (ru)
DE (1) DE60143363D1 (ru)
DK (1) DK1356822T3 (ru)
EA (1) EA005138B1 (ru)
HK (1) HK1063726A1 (ru)
MX (1) MXPA03005032A (ru)
NZ (1) NZ526282A (ru)
PE (1) PE20020572A1 (ru)
UY (1) UY27059A1 (ru)
WO (1) WO2002045746A2 (ru)
ZA (1) ZA200304411B (ru)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1358910A1 (de) * 2002-05-02 2003-11-05 B.R.A.H.M.S Aktiengesellschaft Verfahren und Mittel zur Prävention, Hemmung und Therapie von Krebserkrankungen
EP1367395A1 (de) * 2002-05-02 2003-12-03 B.R.A.H.M.S Aktiengesellschaft Diagnose von Neoplasmen mit Hilfe von anti-Gangliosid-Antikörpern
CU23257A1 (es) * 2003-02-27 2008-01-24 Centro Inmunologia Molecular COMPOSICIONES VACUNALES A BASE DE GANGLIOSIDOS PARA LA ADMINISTRACION SUBCUTáNEA
AR045815A1 (es) * 2003-10-09 2005-11-16 Ct Ingenieria Genetica Biotech Composiciones farmaceuticas que contienen antigenos del virus de papiloma humano
WO2005111079A2 (en) * 2004-05-14 2005-11-24 The United States Of America As Represented By The Secretary Department Of Health And Human Services Hiv vaccine immunogens and immunization strategies to elicit broadly-neutralizing anti-hiv-1 antibodies against the membrane proximal domain of hiv gp41
WO2010003219A1 (en) * 2008-06-17 2010-01-14 Universite Laval Compositions comprising salmonella porins and uses thereof as adjuvants and vaccines
PT2654785T (pt) * 2010-12-22 2019-06-25 Bayer Ip Gmbh Resposta imunitária melhorada em espécies bovinas
KR101323845B1 (ko) * 2011-01-21 2013-10-31 광주과학기술원 외막소포체를 유효성분으로 포함하는 항암용 약제학적 조성물
CU24070B1 (es) * 2011-12-27 2015-01-29 Ct De Inmunología Molecular Composiciones farmacéuticas para el tratamiento de tumores que expresan regf y gangliósidos n-glicolilados gm3 (neugcgm3)
MX2015012461A (es) * 2013-03-15 2016-08-08 Bioven 3 Ltd Proteinas sintéticas autoensamblables.
CU24299B1 (es) * 2013-08-02 2017-12-08 Centro De Inmunología Molecular Composiciones vacunales bivalentes basadas en los receptores de tipo 1 y 2 del factor de crecimiento epidérmico
US10105306B2 (en) * 2013-09-17 2018-10-23 Bestop Group Holdings Limited Method of preparing a growth factor concentrate
HK1194912A2 (en) * 2013-09-17 2014-10-24 Bestop Group Holdings Ltd Growth factor concentrate and the use thereof
CN106103467B (zh) * 2014-03-11 2019-12-31 艾克斯-马赛大学 与细胞膜神经节苷脂相互作用的嵌合肽
EP3597214A1 (en) 2017-03-15 2020-01-22 Centro de Inmunologia Molecular Method for the treatment of patients with carcinomas
US12019073B2 (en) * 2017-03-15 2024-06-25 Centro De Inmunologia Molecular Method for the treatment of patients with carcinomas
AU2018341578B2 (en) * 2017-09-27 2024-02-08 L2 Diagnostics, Llc ErbB peptide pharmaceutical and vaccine compositions and therapeutics uses thereof for cancer
CU24534B1 (es) * 2017-11-06 2021-07-02 Ct Inmunologia Molecular Adyuvantes nano-particulados que contienen variantes sintéticas del gangliósido gm3
CU20170173A7 (es) 2017-12-27 2019-11-04 Ct Inmunologia Molecular Nano-partículas que contienen el gangliósido gm3 como inmunomoduladoras
CN109865137A (zh) * 2019-01-23 2019-06-11 天德悦（北京）生物科技有限责任公司 经碘代乙酰基活化的琼脂糖微球在提高多肽或蛋白类免疫原免疫原性中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4857637A (en) * 1986-05-07 1989-08-15 Genentech, Inc. Methods and compositions for immunologically modulating growth hormone receptor activity
IT1206250B (it) * 1987-02-18 1989-04-14 Ist Farmacoterapico It Spa Stiche umane e relativi prodotti metodo per l'estrazione di antigeni di membrana aventi proprieta' immunogene a partire da cellule neopla-
US5726292A (en) * 1987-06-23 1998-03-10 Lowell; George H. Immuno-potentiating systems for preparation of immunogenic materials
EP0651656A1 (en) 1992-07-08 1995-05-10 Schering Corporation Use of gm-csf as a vaccine adjuvant
EP0657471B1 (en) * 1993-12-09 2001-10-24 Centro de Inmunologia Molecular Anti ganglioside monoclonal antibodies and their use in the specific active immunotherapy of malignant tumours
US6149921A (en) * 1993-12-29 2000-11-21 Centro De Inmunologia Molecular Vaccine compositions for eliciting an immune response against N-acetylated gangliosides and their use for cancer treatment
CU22420A1 (es) * 1993-12-29 1996-01-31 Centro Inmunologia Molecular Composicion vacunal para el desarrollo de una respuesta contra gangliosidos n glicolilados y su uso para el tratamiento del cancer
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US6207170B1 (en) * 1998-01-16 2001-03-27 Biomira U.S.A., Inc. Patient-specific white blood cell malignancy vaccine from membrane-proteoliposomes

Also Published As

Publication number Publication date
AR031638A1 (es) 2003-09-24
CN1484532A (zh) 2004-03-24
MXPA03005032A (es) 2004-09-10
AU2151902A (en) 2002-06-18
NZ526282A (en) 2005-01-28
ZA200304411B (en) 2004-07-29
ATE485833T1 (de) 2010-11-15
BR0116013A (pt) 2004-01-06
US20020136735A1 (en) 2002-09-26
CA2431188A1 (en) 2002-06-13
EP1356822B1 (en) 2010-10-27
KR100850473B1 (ko) 2008-08-07
WO2002045746A3 (es) 2002-12-27
CN1291755C (zh) 2006-12-27
AU2002221519B2 (en) 2006-11-23
BRPI0116013B1 (pt) 2018-07-24
EA005138B1 (ru) 2004-12-30
UY27059A1 (es) 2002-04-26
JP2004523494A (ja) 2004-08-05
DK1356822T3 (da) 2011-02-07
BRPI0116013B8 (pt) 2021-05-25
PE20020572A1 (es) 2002-07-31
JP4210519B2 (ja) 2009-01-21
KR20030061838A (ko) 2003-07-22
EP1356822A2 (en) 2003-10-29
CA2431188C (en) 2010-09-07
HK1063726A1 (en) 2005-01-14
WO2002045746A2 (es) 2002-06-13
DE60143363D1 (de) 2010-12-09
US7776342B2 (en) 2010-08-17

Similar Documents

Publication Publication Date Title
EA200300640A1 (ru) Фармацевтические композиции, усиливающие иммуногенность антигенов со слабой иммуногенностью
DK1002110T3 (da) Immunsvar mod HPV-antigener fremkaldt af sammensætninger, som omfatter et HPV-antigen og et stressprotein eller en ekspressionsvektor i stand til at ekspressere disse proteiner
ES2141750T5 (es) Composicion que contiene a la vez una forma soluble y una forma insoluble de un inmunogeno.
EP2275552A3 (en) Neisserial antigenic peptides
GB2255093A (en) Hiv-1 core protein fragments
DK1098910T3 (da) Antigenkompleks indeholdende immunstimulerende peptid, CD4 og chemokinreceptordomæne til behandling af HIV og immunsygdomme
WO2007034489A3 (en) Immunogenic fragments of t-cell receptor constant domains and peptides derived therefrom
ATE389397T1 (de) Adjuvante zusammensetzungen
Gupta et al. Vaccine adjuvants: the current necessity of life
AU2016201589B2 (en) Peptide adjuvants
FR2636842B1 (fr) Proteine de fusion d'une sequence derivee de la sous-unite b de la toxine cholerique et d'un antigene heterologue doue de proprietes immunogenes, compositions de vaccins les contenant et acides nucleiques recombinants contenant une sequence de nucleotides codant pour ladite proteine de fusion
ATE283065T1 (de) Mehrzweckvakzine gegen umhüllte viren
ATE374244T1 (de) Identifizierung von antigenen peptiden durch zytotoxische t-lymphozyten aktiviert von dendritischen zellhybriden
DK0952771T3 (da) Hidtil ukendte saponinpræparater og anvendelser deraf
CN105031646A (zh) 抗肿瘤疫苗佐剂、其制备方法和编码核酸以及抗肿瘤疫苗组合物
Messner et al. Vaccine development based on S-layer technology
MY129626A (en) Preparations that potentiate immunogenicity in low immunogenic antigens
CU23009A1 (es) Preparaciones para potenciar la inmunogenicidad depreparaciones para potenciar la inmunogenicidad de antígenos poco inmunogénicos antígenos poco inmunogénicos
ES2353857T3 (es) Composiciones farmacéuticas que mejoran la inmunogenicidad de antígenos poco inmunogénicos.
AU2001281943A1 (en) The t-cell protein (tzon7), peptides and antibodies derived therefrom and uses thereof
Pumpens et al. Presentation of virus-neutralizing epitopes on the surface of chimeric viral capsids
Chengua et al. Gene fusion of cholera toxin B subunit with HBV PreS epitope and overexpression in E. coli
Jenkins et al. Enhanced delivery systems for enteric antigen uptake in teleosts
Smith et al. Potential for GTF-based synthetic peptides in a dental caries vaccine
CN104744594A (zh) 乙肝病毒多表位与志贺毒素的融合蛋白及其制备方法和应用

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY

MK4A Patent expired

Designated state(s): RU